A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer

@article{Bilgin2017ACA,
  title={A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer},
  author={Burak Bilgin and Mehmet A N Şendur and Didem Şener Dede and Muhammed Bulent Akinci and Bulent Yalcin},
  journal={Current Medical Research and Opinion},
  year={2017},
  volume={33},
  pages={1559 - 1569}
}
Abstract Background: Resistance to endocrine treatment generally occurs over time, especially in the metastatic stage. In this paper, we aimed to review the mechanisms of cyclin-dependent kinase (CDK) 4/6 inhibition and clinical usage of new agents in the light of recent literature updates. Scope: A literature search was carried out using PubMed, Medline and ASCO and ESMO annual-meeting abstracts by using the following search keywords; “palbociclib”, “abemaciclib”, “ribociclib”, “cyclin… Expand
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
TLDR
This review focuses on the research progress on CDK4/6 inhibitors in NSCLC, particularly the mechanisms of action, drugs, clinical research progress, and future application. Expand
Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
TLDR
It is asserted that, going forward, a new treatment pattern for cancer may be a combination therapy with a cell cycle inhibitor and a molecular targeted drug. Expand
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
TLDR
The crucial roles of CDK4/6 in regulating the cell cycle and cancer cells are discussed, the rationale for selectively inhibiting CDK 4/6 for cancer treatment is analyzed, the latest advances in highly selective CDK2/6 inhibitors with different chemical scaffolds are reviewed, and the mechanisms associated with CDK3/6 inhibitor resistance are explained. Expand
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials
TLDR
The addition of CDK 4/6 inhibitors (either abemaciclib, palbocic lib, or ribociclib) to an AI (anastrozole or letrozoles) significantly improved PFS, overall response rate, and clinical benefit rate in comparison with a nonsteroidal AI alone. Expand
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
TLDR
Many of the recently reported clinical trials that led to the approval of these new drugs in the first-line settings, along with the current international guidelines are reviewed. Expand
Anti-cancer Dynamics of Natural Phytochemical Inhibitors of Cyclin-Dependent Kinases
TLDR
This chapter aims to discuss the molecular and cellular mechanisms by which natural CDK inhibitors mediate their anti-cancer responses, and to compare the effects of natural compounds to pharmacologically designed drugs that inhibit CDK activity. Expand
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
TLDR
Palbociclib in combination with endocrine therapy shows an unexpectedly high CBR and favorable safety profile in heavily pretreated endocrine-resistant estrogen receptor-positive, HER2-negative MBC patients. Expand
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
TLDR
Main co-crystals of CDKs in complex with corresponding inhibitors reported in recent years are reviewed, focusing on the binding models and the pharmacological activities of inhibitors. Expand
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
TLDR
It is reported that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation, involving as critical mechanistic events loss of the CDKI p21CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Expand
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
TLDR
It is reported that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2-activation, involving as a critical mechanistic events loss of the CDK inhibitor p21CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 82 REFERENCES
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
TLDR
Recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK 4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. Expand
Cyclin‐Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future
TLDR
O Ongoing clinical trials should provide additional information to guide the appropriate use of these agents and identify patient populations that could derive the most benefit. Expand
CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update
TLDR
The preclinical and clinical development of potent and selective CDK4/6 inhibitors are reviewed, as well as the role for novel applications of these agents outside the arena of HR-positive, HER2-negative advanced breast cancer are discussed. Expand
Treating cancer with selective CDK4/6 inhibitors
TLDR
Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. Expand
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
TLDR
It is reported that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents. Expand
Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
TLDR
Phosphoproteomic analysis of palbociclib-resistant ER+ breast cancer cell lines demonstrated up-regulation of PI3K/AKT/mTOR and anti-apoptotic pathways, and targeted drug screening showed a variable pattern across resistant clones with increased sensitivity to co-treatment with AKT inhibitors, AKT alpha/delta inhibitors and/or MEK inhibitors in selected resistant clones. Expand
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
TLDR
This open-label, randomised phase 2 study aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer. Expand
Preclinical and clinical development of cyclin-dependent kinase modulators.
TLDR
Modulation of cdk activity is an attractive target for cancer chemotherapy, and several agents that modulatecdk activity are in or are approaching entry into clinical trials. Expand
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
TLDR
Single-agent palbociclib is well tolerated and active in patients with endocrine-resistant, HR+, Rb-positive breast cancer and no biomarker identified a sensitive tumor population. Expand
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
TLDR
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group. Expand
...
1
2
3
4
5
...